No known gene associations, inheritance patterns, or molecular mechanism data are certified in this packet for nasopharyngeal carcinoma. Etiologic and genetic information is not certifiable from packet data and is therefore not described here.

No diagnostic methods are certified in this packet for nasopharyngeal carcinoma. Diagnostic criteria, laboratory findings, and imaging protocols are not certifiable from packet data and are therefore not described here. No newborn screening information is applicable to this condition.

LOQTORZI (toripalimab-tpzi) is the FDA-approved treatment recorded in this packet (BLA, CDER, approved October 2023, market status ACTIVE). No foundational therapies, additional approved drugs, or patient assistance programs are certified in this packet. Investigational approaches documented in this packet include orphan-designated agents: an EBV-targeting cellular immunotherapy, a CAR-T cell product directed against EBV glycoprotein 350, and the nanatinostat plus valganciclovir combination (all carry DESIGNATED status only — not FDA approval). All designated agents listed represent investigational candidates, not currently available treatments.

No natural history data, survival data, or prognostic information is certified in this packet for nasopharyngeal carcinoma. Prognosis is not certifiable from the available packet data.

Numerous active clinical trials for nasopharyngeal carcinoma are documented in this packet. Trial details include a Phase 3 study of radiotherapy plus nimotuzumab or cisplatin (NCT04456322, Sun Yat-sen University), a Phase 2 consolidation immunotherapy study with nivolumab following chemoradiotherapy (NCT04910347, Yonsei University), and a Phase 2 study of becotatug vedotin combined with a PD-1 inhibitor in recurrent nasopharyngeal carcinoma (NCT07781358). Active clinical trials for this condition are listed on ClinicalTrials.gov.